Compare Stocks: ADCT, ARVN, ZURA, and STTK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.01 -4.3%	$1.15	$0.78 ▼ $4.98	$128.46M	1.89	875,058 shs	1.34 million shs
ARVN Arvinas	$8.97 -0.4%	$8.16	$6.95 ▼ $14.51	$581.33M	1.71	913,368 shs	461,094 shs
STTK Shattuck Labs	$7.42 +1.4%	$6.43	$0.79 ▼ $8.33	$568.97M	1.08	1.12 million shs	640,742 shs
ZURA Zura Bio	$5.57 -1.1%	$4.99	$1.64 ▼ $7.44	$534.18M	-0.02	698,267 shs	794,583 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	-3.83%	-10.59%	-21.79%	-69.15%	-67.48%
ARVN Arvinas	-0.44%	+2.51%	+8.33%	-1.21%	+26.52%
STTK Shattuck Labs	+1.37%	+2.06%	+9.60%	+18.53%	+815.26%
ZURA Zura Bio	-1.07%	-6.70%	+3.34%	+18.01%	+250.31%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.01 -4.3%	$1.15	$0.78 ▼ $4.98	$128.46M	1.89	875,058 shs	1.34 million shs
ARVN Arvinas	$8.97 -0.4%	$8.16	$6.95 ▼ $14.51	$581.33M	1.71	913,368 shs	461,094 shs
STTK Shattuck Labs	$7.42 +1.4%	$6.43	$0.79 ▼ $8.33	$568.97M	1.08	1.12 million shs	640,742 shs
ZURA Zura Bio	$5.57 -1.1%	$4.99	$1.64 ▼ $7.44	$534.18M	-0.02	698,267 shs	794,583 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	-3.83%	-10.59%	-21.79%	-69.15%	-67.48%
ARVN Arvinas	-0.44%	+2.51%	+8.33%	-1.21%	+26.52%
STTK Shattuck Labs	+1.37%	+2.06%	+9.60%	+18.53%	+815.26%
ZURA Zura Bio	-1.07%	-6.70%	+3.34%	+18.01%	+250.31%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	2.33	Hold	$6.25	521.89% Upside
ARVN Arvinas	2.45	Hold	$14.17	57.93% Upside
STTK Shattuck Labs	2.82	Moderate Buy	$12.13	63.41% Upside
ZURA Zura Bio	2.75	Moderate Buy	$14.00	151.35% Upside

Current Analyst Ratings Breakdown

Latest ADCT, ARVN, ZURA, and STTK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	ARVN Arvinas	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D)
8/12/2026	ZURA Zura Bio	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$15.00 ➝ $22.00
8/12/2026	ZURA Zura Bio	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$15.00 ➝ $20.00
8/11/2026	STTK Shattuck Labs	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$18.00 ➝ $14.00
8/10/2026	ARVN Arvinas	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$10.00
8/10/2026	ARVN Arvinas	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$14.00
8/10/2026	ARVN Arvinas	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$24.00 ➝ $21.00
8/5/2026	ARVN Arvinas	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$11.00 ➝ $12.00
8/5/2026	ARVN Arvinas	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/4/2026	ARVN Arvinas	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$15.00 ➝ $11.00
8/4/2026	ARVN Arvinas	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$79.58M	1.61	N/A	N/A	($1.50) per share	-0.67
ARVN Arvinas	$316.70M	1.83	N/A	N/A	$8.71 per share	1.03
STTK Shattuck Labs	$1M	568.97	N/A	N/A	$2.75 per share	2.70
ZURA Zura Bio	N/A	N/A	N/A	N/A	$2.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$142.62M	-$0.66	N/A	N/A	N/A	-121.77%	N/A	-32.15%	N/A
ARVN Arvinas	-$80.80M	$0.10	89.71	N/A	N/A	2.94%	1.91%	1.29%	N/A
STTK Shattuck Labs	-$48.81M	-$0.51	N/A	N/A	N/A	N/A	-43.57%	-40.90%	N/A
ZURA Zura Bio	-$99.35M	-$1.13	N/A	N/A	N/A	N/A	-56.13%	-50.15%	N/A

Latest ADCT, ARVN, ZURA, and STTK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ADCT ADC Therapeutics	-$0.2160	-$0.11	+$0.1060	-$0.11	$18.89 million	$19.25 million
8/11/2026	Q2 2026	STTK Shattuck Labs	-$0.1241	-$0.12	+$0.0041	-$0.12	N/A	N/A
8/11/2026	Q2 2026	ZURA Zura Bio	-$0.1913	-$0.21	-$0.0187	-$0.21	N/A	N/A
8/4/2026	Q2 2026	ARVN Arvinas	-$0.3741	$2.58	+$2.9541	$2.58	$60.71 million	$249.70 million
6/30/2026	Q2 2026	ZURA Zura Bio	N/A	-$0.21	N/A	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
ARVN Arvinas	N/A	N/A	N/A	N/A	N/A
STTK Shattuck Labs	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	4.09	4.02
ARVN Arvinas	N/A	7.91	7.91
STTK Shattuck Labs	N/A	27.59	22.06
ZURA Zura Bio	N/A	12.90	19.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
ARVN Arvinas	95.19%
STTK Shattuck Labs	58.74%
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.10%
ARVN Arvinas	7.30%
STTK Shattuck Labs	8.79%
ZURA Zura Bio	12.37%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	310	127.19 million	120.70 million	Optionable
ARVN Arvinas	420	64.52 million	59.81 million	Optionable
STTK Shattuck Labs	100	76.68 million	69.94 million	Optionable
ZURA Zura Bio	3	94.88 million	83.14 million	Optionable

ADCT, ARVN, ZURA, and STTK Headlines

Recent News About These Companies

Zura Bio (NASDAQ:ZURA) Announces Quarterly Earnings Results

August 11, 2026 | marketbeat.com

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

August 11, 2026 | businesswire.com

Zura Bio (ZURA) Projected to Release Quarterly Earnings on Thursday

August 6, 2026 | americanbankingnews.com

Zura Bio (ZURA) Projected to Announce Earnings on Thursday

August 6, 2026 | marketbeat.com

Zura Bio (NASDAQ:ZURA) Rating Increased to Sell at Wall Street Zen

August 1, 2026 | marketbeat.com

Stempoint Capital LP Makes New Investment in Zura Bio Limited $ZURA

July 30, 2026 | marketbeat.com

1,179,715 Shares in Zura Bio Limited $ZURA Purchased by EcoR1 Capital LLC

July 28, 2026 | marketbeat.com

Zura Bio Stock (NASDAQ:ZURAW), Analyst Ratings, Price Targets, Predictions

July 27, 2026 | benzinga.com

Zura Bio (NASDAQ:ZURA) Shares Up 7.8% - Still a Buy?

July 27, 2026 | marketbeat.com

Commodore Capital LP Invests $19.34 Million in Zura Bio Limited $ZURA

July 27, 2026 | marketbeat.com

Zura Bio Limited $ZURA Shares Acquired by Affinity Asset Advisors LLC

July 25, 2026 | marketbeat.com

Siren L.L.C. Acquires 2,434,866 Shares of Zura Bio Limited $ZURA

July 24, 2026 | marketbeat.com

Zura Bio Limited (NASDAQ:ZURA) Receives Average Rating of "Moderate Buy" from Analysts

July 23, 2026 | marketbeat.com

Zura Bio (NASDAQ:ZURA) Stock Price Up 5.3% - Time to Buy?

July 17, 2026 | marketbeat.com

William Blair Starts Zura Bio (ZURA) at Outperform

July 14, 2026 | uk.finance.yahoo.com

Licensing a potential first-in-class, anti-IL-17 and anti-BAFF dual antagonist

July 9, 2026 | businesswire.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Qiagen (QGEN) and Zura Bio (ZURA)

July 9, 2026 | theglobeandmail.com

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

June 29, 2026 | finance.yahoo.com

Zura Bio (ZURA) Gets a Buy from Oppenheimer

June 13, 2026 | theglobeandmail.com

Here's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Situation

June 3, 2026 | finance.yahoo.com

Zura Bio Announces Board Resignation, Governance Stability Affirmed

May 22, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT, ARVN, ZURA, and STTK Company Descriptions

ADC Therapeutics NYSE:ADCT

$1.00 -0.05 (-4.29%)

Closing price 08/14/2026 03:59 PM Eastern

Extended Trading

$1.01 +0.01 (+0.50%)

As of 08/14/2026 07:59 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Arvinas NASDAQ:ARVN

$8.97 -0.04 (-0.44%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$8.93 -0.04 (-0.48%)

As of 08/14/2026 07:43 PM Eastern

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Shattuck Labs NASDAQ:STTK

$7.42 +0.10 (+1.37%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$7.49 +0.07 (+0.94%)

As of 08/14/2026 07:36 PM Eastern

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

Zura Bio NASDAQ:ZURA

$5.57 -0.06 (-1.07%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$5.69 +0.12 (+2.14%)

As of 08/14/2026 07:34 PM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADCT, ARVN, ZURA, and STTK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADCT, ARVN, ZURA, and STTK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADCT, ARVN, ZURA, and STTK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT, ARVN, ZURA, and STTK Company Descriptions

ADC Therapeutics NYSE:ADCT

Arvinas NASDAQ:ARVN

Shattuck Labs NASDAQ:STTK

Zura Bio NASDAQ:ZURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ADCT, ARVN, ZURA, and STTK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ADCT, ARVN, ZURA, and STTK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ADCT, ARVN, ZURA, and STTK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT, ARVN, ZURA, and STTK Company Descriptions

ADC Therapeutics NYSE:ADCT

Arvinas NASDAQ:ARVN

Shattuck Labs NASDAQ:STTK

Zura Bio NASDAQ:ZURA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools